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25(OH)D3-enriched or fortiﬁed foods are more efﬁcient at tackling
inadequate vitamin D status than vitamin D3
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The ability to synthesise sufﬁcient vitamin D through sunlight in human subjects can be
limited. Thus, diet has become an important contributor to vitamin D intake and status;
however, there are only a few foods (e.g. egg yolk, oily ﬁsh) naturally rich in vitamin
D. Therefore, vitamin D-enriched foods via supplementing the animals’ diet with vitamin
D or vitamin D fortiﬁcation of foods have been proposed as strategies to increase
vitamin D intake. Evidence that cholecalciferol (vitamin D3) and calcifediol (25(OH)D3)
content of eggs, ﬁsh and milk increased in response to vitamin D3 supplementation of
hens, ﬁsh or cows’ diets was identiﬁed when vitamin D-enrichment studies were reviewed.
However, evidence from supplementation studies with hens showed only dietary 25(OH)D3,
not vitamin D3 supplementation, resulted in a pronounced increase of 25(OH)D3 in the
eggs. Furthermore, evidence from randomised controlled trials indicated that a 25(OH)D3
oral supplement could be absorbed faster and more efﬁciently raise serum 25(OH)D
concentration compared with vitamin D3 supplementation. Moreover, evidence showed
the relative effectiveness of increasing vitamin D status using 25(OH)D3 varied between
3·13 and 7·14 times that of vitamin D3, probably due to the different characteristics of
the investigated subjects or study design. Therefore, vitamin D-enrichment or fortiﬁed
foods using 25(OH)D3 would appear to have advantages over vitamin D3. Further well-
controlled studies are needed to assess the effects of 25(OH)D3 enriched or fortiﬁed foods
in the general population and clinical patients.
Enrichment: Fortiﬁcation: 25(OH)D3: Vitamin D3: Vitamin D deﬁciency
Vitamin D is usually synthesised in skin that is exposed to
UV radiation, which has led to the term ‘sunshine vita-
min’(1). Traditionally, the primary role of vitamin D is
related to calcium absorption and bone health. Children
and adults with vitamin D deﬁciency have an increased
risk of developing rickets or osteomalacia(2). Recently, a
resurgence of childhood rickets has highlighted the need
for adequate vitamin D status in many parts of the
world(3–5). Furthermore, mounting evidence from epi-
demiological studies indicates that vitamin D status is
inversely associated with the risk of CVD, cancers and
diabetes(1,6), although there is some uncertainty about
what deﬁnes an adequate vitamin D status(7).
Vitamin D deﬁciency is prevalent and is considered
a serious issue throughout the world(8–10), even in sunnier
climates such as Australia and New Zealand(11).
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Recently, the Scientiﬁc Advisory Committee on
Nutrition(7) reported that in the UK, 22–24 % of adults
aged 19–64 years, and 17–24 % of those ≥65 years were
vitamin D deﬁcient (plasma 25-hydroxyvitamin D3
(25(OH)D3) <25 nmol/l). There are several factors that
have contributed to the low vitamin D status commonly
seen today, such as lifestyle changes (increased indoor
lifestyle, sun screens use) and human characteristics
(e.g. ageing, clothing, increased obesity, low-fat diet
trend)(12). Therefore, foods that contribute to vitamin
D intake have become more important than before.
However, there are only a few foods naturally rich in
vitamin D, such as oily ﬁsh and egg yolks(13).
The aim of this review is ﬁrst to critically evaluate the
existing evidence on whether the vitamin D content of
animal-derived foods can be increased by feeding chole-
calciferol (vitamin D3) and/or calcifediol (25(OH)D3)
supplements to laying hens, ﬁsh and cows. Second, the
present review summaries evidence from the human ran-
domised controlled trials (RCT), which include the
effects of 25(OH)D3 supplementation on increasing
serum/plasma 25(OH)D3 concentration.
Vitamin D absorption, synthesis and metabolism
Generally, the term vitamin D refers to both vitamin D2
and vitamin D3. Vitamin D2 is produced by fungi, while
vitamin D3 is produced by human subjects and ani-
mals(14). Human subjects usually synthesise vitamin D3
in the skin(15) where 7-dehydrocholesterol in the epider-
mis is converted to pre-vitaminD3 when skin is exposed to
sunlight. Then, pre-vitamin D3 undergoes a temperature-
dependent isomerisation to vitamin D3 over a period of
approximately 3 d(6). Vitamin D (vitamin D2 or vitamin
D3) can also be obtained from the diet
(15) and it is
absorbed with long-chain TAG in the small intestine(16).
It is then incorporated into chylomicrons and trans-
ported in lymph to the blood and into the general
circulation(17).
After entering the circulation, there are two hydroxyl-
ation reactions to convert vitamin D to the biologically
active form(6). The ﬁrst hydroxylation reaction is in the
liver where vitamin D is hydroxylated to 25(OH)D
by the vitamin D-25-hydroxylase enzyme. The second
hydroxylation reaction is in the kidney where 25(OH)D
is converted to 1,25(OH)2D by 25-hydroxyvitamin
D-1α-hydroxylase(6), and the 1,25(OH)2D metabolite is
the biologically active form of vitamin D(18).
Foods of animal origin as dietary sources of vitamin D
Vitamin D content of vitamin D-enriched foods can dif-
fer considerably between food retailers. One US retail
study analysed the vitamin D content of egg yolks col-
lected from twelve individual retail supermarkets across
the country and reported a broad range of vitamin D3
and 25(OH)D3 concentrations of 9·7–18 and 4·3–13·2
µg/kg, respectively(19). In addition, our recent UK
retail study(20) showed vitamin D3 and 25(OH)D3
concentrations of eggs were signiﬁcantly different
depending on the egg production systems. Egg yolks pro-
duced by birds kept in indoor systems had much lower
concentrations (40·2 (SE 3·1) µg/kg) of vitamin D3 than
the egg yolks produced from outdoor systems (57·2 (SE
3·2) µg/kg), while 25(OH)D3 concentrations of the eggs
were higher in organic eggs only. Similarly, the vitamin
D contents of ﬁsh have been shown to vary according
to the production systems. The study of Lu et al.(21) indi-
cated the vitamin D3 content of wild salmon to be three
times higher than that of farmed salmon; however, the 25
(OH)D3 content of the salmon was not measured. In
addition, other studies(22,23) have shown the 25(OH)D3
content of several species of marine and freshwater ﬁsh
to be <0·02 µg/100 g. Therefore, foods generally regarded
as rich sources of vitamin D may not be sustainable vita-
min D contributors for the general population, due to
variability in vitamin D content, which in turn may be
inﬂuenced by production systems or different species
(genotype). Furthermore, the National Diet and
Nutrition Survey of the UK(24) reported that the average
daily intake of vitamin D for adults was 3·1 µg for men
and 2·6 µg for women, which is much lower than the
UK vitamin D reference nutrition intake of 10 µg/d(7).
Therefore, vitamin D-enriched or fortiﬁed foods are
needed to ensure an adequate vitamin D intake for the
general population.
Enrichment of animal-derived foods as dietary sources of
vitamin D
Vitamin D-enriched eggs
In general, there are two main methods to enrich the vita-
min D content of eggs: increased sunlight exposure and
vitamin D supplementation of the birds’ diet. Because
hens can synthesise vitamin D from natural sunlight
exposure, free-range egg production system may be an
inexpensive way to increase their vitamin D content. A
study by Kuhn et al. assigned laying hens to a free-range
treatment or an indoor treatment for over 4 weeks and
found that eggs from the free-range group, which were
exposed to sunlight, had signiﬁcantly higher vitamin D3
content (mean 14·3 µg/100 g DM) than eggs from the
indoor group (mean 3·8 µg/100 g DM)(25). Furthermore,
there are several studies which have shown that the vitamin
D3 content of eggs can be enhanced by feeding vitamin
D3 supplements to the hens (Table 1)
(26–32). The
results of all studies revealed that egg yolk vitamin D3
concentration was efﬁciently increased by vitamin D3
dietary supplementation. The study of Yao et al. showed
a linear dose–response relationship existed between vita-
min D3 dietary supplementation and vitamin D3 concen-
trations of egg yolks(30). Moreover, as 25(OH)D3 is a
metabolite of vitamin D3, the 25(OH)D3 content in eggs
can also be enhanced by supplementing the birds’ diet
with vitamin D3. However, the response in 25(OH)D3 con-
tent of egg yolk is much less than that of vitamin D3.
Browning and Cowieson(31) showed that a 4-fold increase
in vitamin D3, and a 2-fold increase in 25(OH)D3 in egg
yolk resulted from a 4-fold increase in the vitamin D3
J. Guo et al.2
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in the diet (62·5–250 µg/kg). Similarly, evidence from
another study showed that the vitamin D3 in egg yolk
was increased approximately 7-fold as a result of feeding
a diet with a 3·5-fold higher vitamin D3 content (from
62·4 to 216 µg/kg), while the corresponding increase in
25(OH)D3 content was only about 1·5-fold
(26).
There are only a few studies(29,31,32) examining the
effect of feeding birds with diets supplemented with 25
(OH)D3. In the EU, 25(OH)D3 has only recently been
authorised for addition to poultry diets, and the max-
imum content of the vitamin D3 and 25(OH)D3 combin-
ation for laying hens is 80 µg/kg(33,34). It is of note that
most of vitamin D supplementation studies(27–31), sum-
marised in Table 1, had higher vitamin D doses than
the EU diet limit(33), thus, the potential for increasing
vitamin D in eggs by adding vitamin D to the diet of
laying hens is limited by EU regulations. Browning and
Cowieson(31) and Duffy et al.(32) both showed an addition
of 25(OH)D3 to the vitamin D3 supplement resulted in
the elevation of the 25(OH)D3 content of the egg yolk,
but there was no signiﬁcant increase in the vitamin D3
content of the egg yolk. Other studies investigated dietary
supplementation with 25(OH)D3
( 29,32), and showed that
only egg yolk 25(OH)D3 was increased, but not vitamin
D3. Therefore, we speculate that 25(OH)D3 in the diet
can be absorbed directly by laying hens without transfer
to vitamin D3 in the circulation.
Vitamin D-enriched ﬁsh
There are very few studies on enriching the vitamin D
content of ﬁsh (Table 2)(35–38). Mattila et al. fed rainbow
trout with different doses of vitamin D3 supplements up
to 539 µg/kg, but no signiﬁcant differences in the vitamin
D3 content of the ﬁsh ﬁllet were observed
(37). In contrast,
the study of Horvli et al. with Atlantic salmon showed
a dose–response relationship between the vitamin D3 in
the diet up to 28·68 mg/kg and vitamin D3 in the ﬁsh
meat(35). Similar high vitamin D3 supplementation doses
were reported in another two studies(36,38), which also
showed that elevated vitamin D3 content of the ﬁsh
liver or whole ﬁsh had been achieved by supplemental
vitamin D3 in the diet. However, 25(OH)D3 contents of
the enriched ﬁsh were not measured in these stud-
ies(35–38), and the lack of evidence on the effects by feed-
ing ﬁsh with 25(OH)D3 on the vitamin D content of the
Table 1. Summary of enrichment studies investigating the impact of adding vitamin D to the diet of laying hens on the vitamin D content of egg
yolks
References
Vitamin D supplement (μg/kg) Feeding
duration
(weeks)
Vitamin D concentration of egg
yolk (μg/100 g)
Vitamin D3 25(OH)D3 Vitamin D3 25(OH)D3
Mattila et al.(26) 26·6 – 6 1·4 0·5
62·4 – 6 3·5 0·9
216·0 – 6 22·0 1·5
Mattila et al.(27) 280·0 – 4 30·0 1·9
Mattila et al.(28) 62·5 – 4 3·8 –
150·0 – 4 13·6 –
375·0 – 4 33·7 –
Browning and Cowieson(31) 62·5 – 9 6·5 1·6
125·0 – 9 10·5 2·1
250·0 – 9 26·2 3·0
Yao et al.(30) 55·0 – 3 3·0 –
242·5 – 3 21·6 –
430·0 – 3 41·0 –
617·5 – 3 60·3 –
2555·0 – 3 870·4 –
Browning and Cowieson(31) 62·5 0 9 6·5 1·6
62·5 34·5 9 6·0 3·3
62·5 69·0 9 4·9 4·5
125·0 0 9 10·5 2·1
125·0 34·5 9 7·4 4·5
125·0 69·0 9 8·1 5·8
250·0 0 9 26·2 3·0
250·0 34·5 9 23·6 3·7
250·0 69·0 9 30·9 8·1
Mattila et al.(29) – 55·0 6 ≤0·2 2·1
– 122·0 6 ≤0·2 4·3
Duffy et al.(32) 37·5 – 4 1·0* 1·9*
75·0 – 4 2·0* 1·9*
37·5 37·5 4 1·3* 3·6*
75·0 4 0·7* 4·4*
25(OH)D3, 25-hydroxyvitamin D3.
* Vitamin D content per egg.
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ﬁsh warrants further research. Again, supplement doses
of the listed studies(35–38) in Table 2 were over the EU
diet limit for farmed ﬁsh of 75 µg/kg(33), which will
limit application in the market.
Vitamin D-enriched milk
A few studies have investigated the longer term effect of
supplemental vitamin D3 on the vitamin D content of the
milk; the summary of these studies is presented in
Table 3(39–42). Hollis et al. showed a 10-fold enhancement
of vitamin D3 intake from 100 to 1000 µg/d resulted in
a 7·5-fold increased vitamin D3 concentration of the
milk and a 2-fold increase in 25(OH)D3
( 39). Moreover,
McDermott et al. compared three different doses of vita-
min D3 with a control diet, and showed an increased con-
centration of vitamin D3 and 25(OH)D3 in the milk
(41).
However, the relationship between increasing dietary
vitamin D3 doses and milk vitamin D3 or 25(OH)D3 con-
centrations were not linear. Furthermore, the study of
Weiss et al. investigated the effect of feeding 450 µg/d
vitamin D3 to pre-calving cows for 13 d which resulted
in concentrations of vitamin D3 and 25(OH)D3 in the
milk ranging from 0·33–0·45 to 0·36–1·02 µg/l, respect-
ively(42). In addition, the study included a diet treatment
of 6 mg vitamin D3 with a cation–anion difference of
−138 mEq/kg daily for 13 d; the concentrations of 25
(OH)D3 in the milk were increased but the treatment
effect disappeared after 28 d. Therefore, evidence from
the limited number of studies(39–42) demonstrated that
milk vitamin D concentrations can be increased by feed-
ing dairy cows with vitamin D supplements. However, it
is of note that the highest milk vitamin D3 and 25(OH)
D3 concentrations were 0·47 and 3·69 µg/l, respectively
(Table 3), which for one typical milk serving of 200 ml
only contributes 0·09 and 0·74 µg vitamin D3 and 25
(OH)D3, respectively, well below the current UK vitamin
D reference nutrition intake of 10 µg/d(7). Furthermore,
the doses of vitamin D in those studies(41,42) were much
higher than the maximum allowed vitamin D content
in EU (0·01 mg/kg diet at 880 g DM/kg approximately
equivalent to 2·27 mg/d)(34), which imposes an even
greater restriction on the possibility of increasing vitamin
D in milk by adding vitamin D supplements in the diet of
dairy cows.
Evidence from human dietary intervention studies with
vitamin D-enriched animal-derived foods
Despite numerous animal-based vitamin D-enrichment
studies on vitamin D in eggs, ﬁsh and milk, there are few
RCT on the effect of consuming vitamin D-enriched
foods on the vitamin D status of the consumer. To our
knowledge, only one recent study has investigated the
weekly effect of consuming seven vitamin D3 or seven
25(OH)D3-enriched eggs on vitamin D status compared
with commercial eggs of ≤2 egg/week(43). After 8 weeks
follow-up in winter, the results showed that while the
serum 25(OH)D of the subjects who consumed commer-
cial eggs decreased from a baseline of 41 (SD 14·1) nmol/l
to 35 (SD 11·4) nmol/l, the serum 25(OH)D of subjects
who consumed vitamin D3-enriched eggs or 25(OH)
D3-enriched eggs was maintained. The serum 25(OH)
D concentrations of subjects who consumed vitamin
D3- or 25(OH)D3-enriched eggs were 50 (SD 21·4) nmol/l
and 49 (SD 16·5) nmol/l, respectively. However, there
was no signiﬁcant difference between vitamin D3- and
25(OH)D3-enriched egg consumption on serum 25(OH)
D concentrations.
Although there are a limited number of human dietary
intervention studies on vitamin D-enriched foods, the
study of Mattila et al.(29) demonstrated that the effect of
foods enriched with either vitamin D3 or 25(OH)D3 on
human vitamin D status depended on their relative effect-
iveness of raising serum or plasma 25(OH)D concentra-
tions. A previous study(44) indicated that there was no
consensus on the relative effectiveness of 25(OH)D3 com-
pared with vitamin D3 for raising human serum or plasma
25(OH)D3 concentrations. Furthermore, UK food com-
position tables(45) indicate that there is no certainty on
the relative potency of 25(OH)D3 compared with vitamin
D3, although it was assumed that 25(OH)D3 had a
potency of ﬁve times that of vitamin D3 for calculating
the total vitamin D of foods(45).
Human intervention studies on the relative effects of
calcifediol and cholecalciferol supplementation on
vitamin D status
Heterogeneity of intervention studies
Eleven RCT that investigated the effects of 25(OH)D3
relative to vitamin D3 were identiﬁed
(46–56) (Table 4).
Nine studies administered 25(OH)D3 supplementation
only, except two studies which provided a combination
supplement of 25(OH)D3 and calcium
(46,49). Five of the
eleven studies(47,49–52) supplemented 25(OH)D3 to gener-
ally healthy subjects, whereas the other six stud-
ies(46,48,53–56) supplemented 25(OH)D3 to clinical
patients. Most studies reported the serum or plasma
Table 2. Summary of enrichment studies investigating the impact of
vitamin D supplemental ﬁsh feeding on vitamin D content of ﬁsh
References
Vitamin D3
supplement
(μg/kg)
Feeding
duration
(weeks)
Vitamin D3 of ﬁsh
(μg/100 g)
Horvli et al.(35) 40 11 1 (ﬁllet)
2210 11 21 (ﬁllet)
28 680 11 210 (ﬁllet)
Vielma et al.(36) 62·5 12 1 (liver)
6250 12 73 (liver)
62 500 12 6900 (liver)
Mattila et al.(37) 89 16 6–15 (ﬁsh ﬁllet)
174 16 6–10 (ﬁsh ﬁllet)
539 16 7–16 (ﬁsh ﬁllet)
Graff et al.(38) 200 9 ≤25 (whole ﬁsh)*
5000 9 80 (whole ﬁsh)*
57 000 9 650 (whole ﬁsh)*
* Estimated from graph.
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25(OH)D concentration at both the beginning and end of
the treatment, except one study(55), which only reported
the 25(OH)D concentration at the end of the treatment.
In terms of the vitamin D status measurement, most stud-
ies measured total 25(OH)D concentration, except two
studies(49,52), which measured 25(OH)D3. For the charac-
teristics of the investigated subjects, ﬁve studies included
both men and women(46,48,51,53,55), while the other studies
only included men or women. In addition, most studies
reported the age and BMI of the subjects, except two stud-
ies(46,48) that did not report the BMI range.
Acute pharmacokinetic action of cholecalciferol and
calcifediol
An early study provided meals with single doses of
25(OH)D3 of 1·5, 5 or 10 µg/kg body weight to gener-
ally healthy subjects and showed that the peak serum
25(OH)D3 concentration was reached within 4–8 h after
ingestion(57). A later study by Jetter et al. compared the
pharmacokinetic absorption of vitamin D3 and 25(OH)
D3 by providing a single dose of 20 µg vitamin D3 or
20 µg 25(OH)D3 to postmenopausal women
(52). The
time to reach maximum plasma 25(OH)D3 concentration
was 22 and 11 h for vitamin D3 and 25(OH)D3, respect-
ively. In addition, the peak concentration of plasma
25(OH)D3 (44 nmol/l) from 25(OH)D3 supplementation
was higher than vitamin D3 supplementation (35 nmol/l),
although they were not signiﬁcantly different. This study
further compared the effect of a higher single dose of
140 µg vitamin D3 and 140 µg 25(OH)D3 with the time
to reach peak plasma 25(OH)D3 being 21 and 4·8 h for
vitamin D3 and 25(OH)D3 supplementation, respect-
ively(52). In addition, the maximum plasma concentration
of 25(OH)D3 for 25(OH)D3 treatment (100 nmol/l)
was signiﬁcantly higher than for vitamin D3 treatment
(44 nmol/l). These results suggest that 25(OH)D3 was
absorbed more quickly than vitamin D3 possibly because
25(OH)D3 has higher solubility in aqueous media than
vitamin D3 due to its more polar chemical structure
(58).
Furthermore, as this metabolite of vitamin D3 is produced
in the liver, the hepatic metabolism of vitamin D3 to
25(OH)D3 is circumvented and consequently the
conversion from vitamin D3 to 25(OH)D3 would be neg-
ligible(59). In patients with liver disease who had an
impaired ability to synthesise 25(OH)D3 from vitamin
D3
( 60), the study of Sitrin and Bengoa(61) veriﬁed that
25(OH)D3 could be absorbed more efﬁciently than vita-
min D3 after oral supplementation. Therefore, supple-
mentation with 25(OH)D3 is not only more efﬁcient at
increasing vitamin D status in generally healthy people,
but may also have a speciﬁc role in tackling lower vitamin
D status in patients who are suffering from liver diseases.
Chronic effects and relative effectiveness of
cholecalciferol and calcifediol treatments
Regarding the expected higher biological effect of
25(OH)D3 in raising serum or plasma 25(OH)D level
after long-term administration, several studies have
conﬁrmed that oral consumption of 25(OH)D3 is highly
effective in raising serum or plasma 25(OH)D level
(Table 4)(46–56). However, the majority of the evidence
in support of a higher impact of 25(OH)D3 supplementa-
tion compared with vitamin D3 on serum or plasma
25(OH)D3 level is from only four studies
(51,52,54,56)
where both 25(OH)D3 and vitamin D3 treatments were
included in the same study (Table 5). The study of
Barger-Lux et al.(47) provided three different doses of
vitamin D3 (25, 250, 1250 µg/d) or 25(OH)D3 (10, 20,
50 µg/d) to the participants for 8 and 4 weeks, respect-
ively. However, the effects of 25(OH)D3 and vitamin
D3 treatments were not directly comparable as the inter-
ventions were not at the same dose or treatment time.
Thus, the study of Barger-Lux et al.(47) was excluded
from the relative effectiveness analysis. In order to com-
pare the relative effectiveness of 25(OH)D3 and vitamin
D3 supplementation on raising serum or plasma 25
(OH)D concentrations, a dose–response factor was cal-
culated for each μg of orally consumed 25(OH)D3 or
vitamin D3 in four studies
(51,52,54,56). The dose–response
factors of 25(OH)D3 and vitamin D3 were calculated
by using endpoint 25(OH)D concentration minus base-
line 25(OH)D concentration, divided by the dose of the
supplementation (dose–response factor = Δ serum/
plasma (mmol/l)/dose (μg)). Then, the relative
Table 3. Summary of enrichment studies investigating the impact of vitamin D supplementation to the diet of dairy cows on vitamin D content of
milk
References
Supplements to diet (μg/d) Vitamin D concentration of milk (μg/l)
Vitamin D3 25(OH)D3 Feeding duration Vitamin D3 25(OH)D3 1,25(OH)2 D3
Hollis et al.(39) 100 – NA 0·04 0·37 0·01
1000 – NA 0·32 0·68 0·004
Reeve et al.(40) 375 – 30 d 0·28 0·15 0·01
Mcdermott et al.(41) 0 – 14 weeks 0·08 0·25 0·10
250 – 14 weeks 0·20 0·43 0·03
1250 – 14 weeks 0·15 0·75 0·13
6250 – 14 weeks 0·33 0·93 0·10
Weiss et al.(42) 450 – 13 d before calving 0·33–0·47 0·36–1·02 –
– DCAD + 6000 13 d before calving – 0·61–3·69 –
25(OH)D3, 25-hydroxyvitamin D3; 1,25(OH)2D3, 1,25 dihydroxyvitamin D3; DCAD, dietary cation–anion difference of −138 mEq/kg.
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Table 4. Summary of study details and serum 25, hydroxyvitamin D (25(OH)D) concentration in long-term randomised controlled trials with calcifediol (25 hydroxyvitamin D3 (25(OH)D3))
supplementation in adults (order by year)
References
Subjects characteristics (trail time during the
year, subjects (sex), age, BMI)
25(OH)D3 supplementation group Control group (if available)
Duration 25(OH)D3 treatment n
Baseline
25(OH)D
(nmol/l)
Endpoint
25(OH)D
(nmol/l) Duration
Vitamin D3
treatment n
Baseline
25(OH)D
(nmol/l)
Endpoint
25(OH)D
(nmol/l)
Hahn et al.(46) Whole year, patients (women and men) with
glucocorticoid-induced osteopenia
46 years, BMI (NA*)
18 months 40 µg/d + 500 mg
calcium/d
9 39 205
Barger-Lux et al.(47) January–April, men
28 years, 26 kg/m2
4 weeks 10 µg/d 7 67 107 8 weeks 25 µg/d 13 67 96
4 weeks 20 µg/d 6 67 143 8 weeks 250 µg/d 10 67 213
4 weeks 50 µg/d 4 67 273 8 weeks 1250 µg/d 14 67 710
Jean et al.(48) March–September, haemodialysis patients
(women and men) 67 years, BMI (NA)
6 months 16 µg /d 149 30 126
Cavalli et al.§(49) April–July, postmenopausal women
65–75 years, 25 kg/m2
12 weeks 125 µg/week +
500 mg calcium/d
25 50 76
12 weeks 250 µg/month +
500 mg calcium/d
28 51 70
12 weeks 500 µg/month +
500 mg calcium/d
27 52 77
Russo et al.(50) January–April, women (7 premenopausal and 11
postmenopausal), 24–72 years, 24 kg/m2
16 weeks 500 µg/month 18 45 105{
Cashman et al.(51) January–April, women and men, 57 years, 29 kg/
m2
10 weeks 20 µg/d 12 38 135 10 weeks 20 µg/d 13 50 69
Jetter et al.{§(52) January–July, postmenopausal women 50–70
years, 18–29 kg/m2
16 weeks 20 µg/d 5 31 173 16 weeks 20 µg/d 5 35 77
Catalano et al.(54) September–March, osteopenic and
dyslipidaemic postmenopausal women
59 years, 27 kg/m2
24 weeks 140 µg once weekly 29 56 126 24 weeks 140 µg once
weekly
28 51 61
Banon et al.(53) Whole year, patients (women and men) had
HIV-infected, 44 years, 15–44 kg/m2
Summer 400 µg once/month 123 37 86 Summer NA 242 53 99
Fall 400 µg once/month 123 37 69 Fall NA 242 53 84
Winter 400 µg once/month 123 37 45 Winter NA 242 53 55
Spring 400 µg once/month 123 37 57 Spring NA 242 53 78
Ortego-Jurado
et al.(55)
Whole year, patients (women and men) had
autoimmune diseases, undergoing
glucocorticoids therapy, 56 years, 28 kg/m2
Spring–
summer
8·85 µg/d 49 NA 84 Spring–
summer
20 µg/d 86 NA 71
Fall–winter 8·85 µg/d 49 NA 89 Fall–winter 20 µg/d 86 NA 61
Navarro-Valverde
et al.(56)
Whole year, postmenopausal osteoporotic
women, 67 years, 26 kg/m2
6 months 20 µg/d 10 37 161 6 months 20 µg/d 10 41 80
12 months 20 µg/d 10 37 188 12 months 20 µg/d 10 41 86
6 months 266 µg once/week 10 38 214
12 months 266 µg once/week 10 38 233
6 months 266 µg once/2
weeks
10 40 165
12 months 266 µg once/2
weeks
10 40 211
* NA, not available.
{ Estimated from graph.
{ Same study of (Jetter et al.(52)) and (Bischoff-Ferrari et al.(62)).
§ Study has measured vitamin D status as 25(OH)D3.
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effectiveness of 25(OH)D3 to vitamin D3 was calculated
by dividing the dose–response factor of 25(OH)D3 by
that of vitamin D3.
The highest relative effectiveness was found in the
study by Catalano et al.(54). Weekly treatment of 140 µg
25(OH)D3 or 140 µg vitamin D3 supplements was pro-
vided to osteopenic and dyslipidaemic postmenopausal
women for 24 weeks. Supplementation with 25(OH)D3
raised serum 25(OH)D from a baseline of 56–126 nmol/l,
while vitamin D3 treatment increased serum 25(OH)D to
a lower extent, from baseline 51 to 61 nmol/l. Thus, the
relative effectiveness factor derived from this study was
7·14, i.e. dietary 25(OH)D3 was 7·14 times more effective
at increasing serum 25(OH)D than dietary vitamin D3.
Vitamin D dietary recommendations are generally
between 10 and 20 µg/d(10), yet, there are few studies
which have compared the effectiveness of dietary
25(OH)D3 and vitamin D3 using doses of 20 µg in their
treatments. Cashman et al.(51) provided daily supple-
ments of 20 µg vitamin D3 or 20 µg 25(OH)D3 to adult
men and women with a mean age of 57 years and with
baseline serum 25(OH)D of 28·9 nmol/l during winter.
After 10 weeks of supplementation, the subjects’ serum
25(OH)D increased to 135 and 69 nmol/l for the
25(OH)D3 and vitamin D3 treatments, respectively. A
relative effectiveness factor of 4·99 was calculated repre-
senting the relative effectiveness of each μg of dietary
25(OH)D3 relative to dietary vitamin D3 for raising
serum 25(OH)D concentration. However, lower relative
effectiveness factors were achieved in other studies
using the same dose of 20 µg vitamin D3 and 25(OH)D3.
Jetter et al. supplemented healthy postmenopausal
women with 20 µg 25(OH)D3 or 20 µg vitamin D3
for 16 weeks during the winter(52). They found that for
the 25(OH)D3 treatment, plasma 25(OH)D3 increased
to 173 nmol/l from a baseline of 31 nmol/l, whereas for
the vitamin D3 treatment, plasma 25(OH)D3 increased
to 77 nmol/l from a baseline level of 35 nmol/l. The rela-
tive effectiveness factor of each μg of 25(OH)D3 was 3·40
compared with vitamin D3 in raising plasma 25(OH)D3
level. A similar low relative effectiveness factor was
found in another study where post-menopausal osteopor-
otic women were given either 20 µg vitamin D3 or 20 µg
25(OH)D3 over 6 or 12 months
(56). The serum concen-
tration of 25(OH)D for the 25(OH)D3 treatment reached
161 and 188 nmol/l from a baseline of 37 nmol/l after 6 or
12 months administration, respectively, while the compar-
able values for the vitamin D3 treatment were an increase
to 80 and 86 nmol/l from a baseline of 41 nmol/l. So the
relative effectiveness factor of 25(OH)D3 relative to vita-
min D3 treatment at 6 and 12 months were 3·13 or 3·29,
respectively.
In summary, of the studies reviewed, the relative
effectiveness of 25(OH)D3 to vitamin D3 for raising vita-
min D status (Table 5), ranged from 3·13 to 7·14.
Previous studies have demonstrated that the season
may have inﬂuences on vitamin D status(13,14). There
were two studies conducted during the winter which
may have minimised any confounding inﬂuence of cuta-
neous vitamin D synthesis from UV radiation (47,51).
Other studies have longer intervention periods of 6
months or more, which could not have avoided some
cutaneous synthesis. Furthermore, baseline status may
be another factor that inﬂuences the relative effectiveness
factor. The study of Catalano et al. had the highest factor
of 7·14 in the present review, and the baseline concentra-
tion of 25(OH)D of the study participants was higher
(>50 nmol/l) than the others(54). Therefore, the different
relative effectiveness seen in different studies may be
due to the different characteristics or genotypes of the
subjects, or different study designs.
Overall, evidence suggests that dietary 25(OH)D3 can
more effectively increase serum 25(OH)D concentrations
than vitamin D3 and may also be absorbed faster reach-
ing a serum or plasma 25(OH)D plateau earlier than
vitamin D3 supplementation. Furthermore, supplementa-
tion with 25(OH)D3 may also have more beneﬁts to
human health compared with vitamin D3 in a general
healthy population. Bischoff-Ferrari et al. reported that
20 µg 25(OH)D3 supplementation over 4 months led to
a 5·7 mmHg decrease in systolic blood pressure and
improvements in several markers of innate immunity in
healthy postmenopausal women(62).
For patients with different diseases and receiving long-
term medication, studies(63–65) showed that several drugs
(e.g. antiepileptic agents, glucocorticoids, antiretroviral
Table 5. Summary of randomised controlled trials with both calcifediol (25 hydroxyvitamin D3 (25(OH)D3)) and vitamin D3 in adults to calculate the
relative effectiveness of 25(OH)D3 and vitamin D3 supplementation in raising serum 25, hydroxyvitamin D (25(OH)D) level
References Treatment (dose, duration) Serum 25(OH)D raising (nmol/l) per 1 μg* Relative effectiveness{
Cashman et al.(51) 20 µg 25(OH)D3/d × 10 weeks 4·82
a 4·99
20 µg vitamin D3/d × 10 weeks 0·97
b
Jetter et al.(52) 20 µg 25(OH)D3/d × 15 weeks 7·12
a 3·40
20 µg vitamin D3/d × 15 weeks 2·51
b
Catalano et al.(54) 140 µg 25(OH)D3/week × 24 weeks 0·50
a 7·14
140 µg vitamin D3/week × 24 weeks 0·07
b
Navarro-Valverde et al.(56) 20 µg 25(OH)D3/d × 6 months 6·19
a 3·13
20 µg vitamin D3/d × 6 months 1·98
b
20 µg 25(OH)D3/d × 12 months 7·54
a 3·29
20 µg vitamin D3/d × 12 months 2·29
b
* Dose–response factor = Δ serum/plasma (mmol/l)/dose (μg).
{Relative effectiveness = a/b within same study.
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or anti-oestrogen drugs) interfered with vitamin D
metabolism, which resulted in patients being more likely
to have low vitamin D status. Thus, it is not only import-
ant to increase vitamin D status in the generally healthy
population but also in patients with speciﬁc illnesses and
receiving certain medication. Therefore, the studies using
25(OH)D3 treatments in patients were also summarised
in Table 4(46,48,53–56), and those studies consistently
reported that chronic 25(OH)D3 supplementation effect-
ively increased serum 25(OH)D concentrations. For
example, Ortego-Jurado et al. showed a lower daily
dose of 8·85 µg 25(OH)D3 to be more effective than a
20 µg dose of vitamin D3 for increasing vitamin D status
in patients with autoimmune disease who were treated
with a low dose of glucocorticoids throughout the
year(55). Similarly, the study of Banon et al. showed
that a monthly dose of 400 µg 25(OH)D3 was safe and
effective at improving vitamin D status of HIV-infected
patients throughout the year(53).
Furthermore, supplementation with 25(OH)D3 may
have additional beneﬁts on patients’ health. Previously,
25(OH)D3 was recommended for patients with kidney
disease since 25(OH)D3 has a direct action on bone
metabolism(66). Hahn et al. provided a daily 40 µg 25
(OH)D3 and 500 mg calcium supplement to patients
who had glucocorticoid-induced osteopenia for 18
months(46). The treatment markedly increased vitamin
D status from 39 to 205 nmol/l. In addition, this study
showed that the 25(OH)D3 treatment improved mineral
and bone metabolism. Jean et al. also offered haemodi-
alysis patients who suffered from vitamin D deﬁciency
with a daily dose of 16 µg 25(OH)D3 for 6 months; vita-
min D status reached 126 nmol/l from 30 nmol/l, at the
same time 25(OH)D3 supplementation corrected the
excess bone turnover(48). Similarly, a study by Catalano
et al.(54) provided 140 µg 25(OH)D3 supplements for 24
weeks to osteopenic and dyslipidaemic postmenopausal
women, and results showed that 25(OH)D3 improved
plasma lipid levels (increased HDL-cholesterol (P =
0·02) and decreased LDL-cholesterol (P= 0·02)) in osteo-
penic and dyslipidaemic postmenopausal women when
added to an ongoing atorvastatin treatment.
As an alternative to vitamin D-enriched foods, vitamin
D fortiﬁcation of foods may also be an option for tack-
ling vitamin D deﬁciency throughout the world. In gen-
eral, fortiﬁcation of foods refers to mandatory and
voluntary fortiﬁcation. The contribution of vitamin
D-fortiﬁed foods to vitamin D intake by the public varies
considerably between countries as there are different
food standard policies(10), and in practice, vitamin D2
or vitamin D3 are used for fortiﬁcation. Evidence from
one previous meta-analysis of RCT showed that vitamin
D3 supplementation is more effective at raising vitamin
D status than vitamin D2
( 67). However, a further compre-
hensive systematic review and meta-analysis of thirty-
three RCT(68) showed that the effect of vitamin D3 sup-
plement on serum 25(OH)D3 response was limited by
the supplemental dose, duration, age of subjects and
baseline level. In addition, the meta-analysis showed a
greater serum or plasma 25(OH)D increase when the
intervention study used a dose of 20 µg/d vitamin D3 or
even higher, with subjects aged >80 years and an
administration period of at least 6–12 months or subjects
had lower baseline 25(OH)D status (<50 nmol/l) than
subjects aged <80 years, administration period <6 months
or subjects had higher baseline 25(OH)D status
(≥50 nmol/l)(68). Therefore, better strategies are needed
to raise vitamin D status of the public throughout life,
and 25(OH)D3-fortiﬁed foods warrant further research.
Conclusions
Vitamin D insufﬁciency has become a world problem,
especially where sunlight exposure is limited by geo-
graphic reasons (latitude), personal characteristics (skin
pigmentation, ageing) or behaviour (sunscreen use,
cultural reasons). However, there are a few natural
foods rich in vitamin D. Thus, vitamin D-enriched
foods produced through a food chain approach such as
feeding animals vitamin D supplements or vitamin
D-fortiﬁed foods are needed to guarantee an adequate
dietary intake of vitamin D by the general population.
The present review summarised the available and
limited number of RCT investigating the effect of
25(OH)D3 supplementation on serum or plasma
25(OH)D concentration. We concluded that it is difﬁcult
to get consensus on the effectiveness of 25(OH)D3 sup-
plementation relative to vitamin D3 for raising vitamin
D status, due to various inﬂuencing factors such as differ-
ent person characteristics (age, BMI), baseline vitamin D
status and time of the year. However, it is unquestionable
that 25(OH)D3 supplementation is more efﬁcient
at raising serum 25(OH)D concentrations and also
appears to be absorbed faster by than the same dose of
vitamin D3. Second, by reviewing available evidence on
vitamin D-enriched eggs, ﬁsh or milk, it is practical
and possible to increase the vitamin D content of eggs,
ﬁsh or milk by addition of vitamin D supplements to
the diet of poultry, ﬁsh or dairy cows. However, the lim-
itations of adding vitamin D to animal feed should be
considered in future enrichment studies. Furthermore,
there are a few RCT investigating the impact of these
vitamin D-enriched foods on improving vitamin D sta-
tus. Therefore, 25(OH)D3-enriched or fortiﬁed foods
should be further explored in the future, and additional
RCT should be conducted to investigate the effect of
25(OH)D3-enriched or fortiﬁed foods on vitamin D sta-
tus of the general population and patients with long-term
health conditions.
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